Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial

David R Gandara, Everett Vokes, Mark Green, Phillip Bonomi, Russell Devore, Robert Comis, David Carbone, Daniel Karp, Chandra Belani

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Purpose: Although several new chemotherapeutic agents are promising as primary therapy in non-small-cell lung cancer (NSCLC), few have demonstrated activity in platinum-refractory disease. Based on encouraging results reported in two single-institution studies of docetaxel in this setting, we performed a multicenter phase II trial evaluating this novel taxane in previously treated NSCLC patients prospectively categorized by platinum response status. Patients and Methods: Eighty patients with NSCLC previously treated with platinum-based chemotherapy received docetaxel at a dose of 100 mg/m2 intravenously over 1 hour, repeated every 21 days, accompanied by dexamethasone 8 mg orally twice daily for 5 days. Forty-seven patients (59%) were defined as platinum-refractory based on response status to prior therapy. Results: The median number of cycles delivered per patient was four (range, one to 21 cycles). Partial response was observed in 13 (16%) of 80 of patients, with similar response rates in platinum-sensitive and platinum- refractory patients. The median survival time was 7 months, and the 1-year survival rate was 25%. Docetaxel was relatively well tolerated in this previously treated population. Grade IV neutropenia was common in patients (77%) but typically of brief duration. Febrile neutropenia was observed in 11 patients (14%), with no fatal infections. Severe fluid retention was rare (4% of patients). Conclusions: This multicenter phase II trial confirms antitumor activity and encouraging survival with docetaxel therapy in platinum-treated and platinum-refractory NSCLC. To validate these results, a phase III trial randomizing platinum-treated patients to docetaxel or best supportive care is underway.

Original languageEnglish (US)
Pages (from-to)131-135
Number of pages5
JournalJournal of Clinical Oncology
Volume18
Issue number1
StatePublished - Jan 2000
Externally publishedYes

Fingerprint

docetaxel
Platinum
Non-Small Cell Lung Carcinoma
Multicenter Studies
Febrile Neutropenia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gandara, D. R., Vokes, E., Green, M., Bonomi, P., Devore, R., Comis, R., ... Belani, C. (2000). Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial. Journal of Clinical Oncology, 18(1), 131-135.

Activity of docetaxel in platinum-treated non-small-cell lung cancer : Results of a phase II multicenter trial. / Gandara, David R; Vokes, Everett; Green, Mark; Bonomi, Phillip; Devore, Russell; Comis, Robert; Carbone, David; Karp, Daniel; Belani, Chandra.

In: Journal of Clinical Oncology, Vol. 18, No. 1, 01.2000, p. 131-135.

Research output: Contribution to journalArticle

Gandara, DR, Vokes, E, Green, M, Bonomi, P, Devore, R, Comis, R, Carbone, D, Karp, D & Belani, C 2000, 'Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial', Journal of Clinical Oncology, vol. 18, no. 1, pp. 131-135.
Gandara, David R ; Vokes, Everett ; Green, Mark ; Bonomi, Phillip ; Devore, Russell ; Comis, Robert ; Carbone, David ; Karp, Daniel ; Belani, Chandra. / Activity of docetaxel in platinum-treated non-small-cell lung cancer : Results of a phase II multicenter trial. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 1. pp. 131-135.
@article{934485ddf3264e418172b35776e6940d,
title = "Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial",
abstract = "Purpose: Although several new chemotherapeutic agents are promising as primary therapy in non-small-cell lung cancer (NSCLC), few have demonstrated activity in platinum-refractory disease. Based on encouraging results reported in two single-institution studies of docetaxel in this setting, we performed a multicenter phase II trial evaluating this novel taxane in previously treated NSCLC patients prospectively categorized by platinum response status. Patients and Methods: Eighty patients with NSCLC previously treated with platinum-based chemotherapy received docetaxel at a dose of 100 mg/m2 intravenously over 1 hour, repeated every 21 days, accompanied by dexamethasone 8 mg orally twice daily for 5 days. Forty-seven patients (59{\%}) were defined as platinum-refractory based on response status to prior therapy. Results: The median number of cycles delivered per patient was four (range, one to 21 cycles). Partial response was observed in 13 (16{\%}) of 80 of patients, with similar response rates in platinum-sensitive and platinum- refractory patients. The median survival time was 7 months, and the 1-year survival rate was 25{\%}. Docetaxel was relatively well tolerated in this previously treated population. Grade IV neutropenia was common in patients (77{\%}) but typically of brief duration. Febrile neutropenia was observed in 11 patients (14{\%}), with no fatal infections. Severe fluid retention was rare (4{\%} of patients). Conclusions: This multicenter phase II trial confirms antitumor activity and encouraging survival with docetaxel therapy in platinum-treated and platinum-refractory NSCLC. To validate these results, a phase III trial randomizing platinum-treated patients to docetaxel or best supportive care is underway.",
author = "Gandara, {David R} and Everett Vokes and Mark Green and Phillip Bonomi and Russell Devore and Robert Comis and David Carbone and Daniel Karp and Chandra Belani",
year = "2000",
month = "1",
language = "English (US)",
volume = "18",
pages = "131--135",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Activity of docetaxel in platinum-treated non-small-cell lung cancer

T2 - Results of a phase II multicenter trial

AU - Gandara, David R

AU - Vokes, Everett

AU - Green, Mark

AU - Bonomi, Phillip

AU - Devore, Russell

AU - Comis, Robert

AU - Carbone, David

AU - Karp, Daniel

AU - Belani, Chandra

PY - 2000/1

Y1 - 2000/1

N2 - Purpose: Although several new chemotherapeutic agents are promising as primary therapy in non-small-cell lung cancer (NSCLC), few have demonstrated activity in platinum-refractory disease. Based on encouraging results reported in two single-institution studies of docetaxel in this setting, we performed a multicenter phase II trial evaluating this novel taxane in previously treated NSCLC patients prospectively categorized by platinum response status. Patients and Methods: Eighty patients with NSCLC previously treated with platinum-based chemotherapy received docetaxel at a dose of 100 mg/m2 intravenously over 1 hour, repeated every 21 days, accompanied by dexamethasone 8 mg orally twice daily for 5 days. Forty-seven patients (59%) were defined as platinum-refractory based on response status to prior therapy. Results: The median number of cycles delivered per patient was four (range, one to 21 cycles). Partial response was observed in 13 (16%) of 80 of patients, with similar response rates in platinum-sensitive and platinum- refractory patients. The median survival time was 7 months, and the 1-year survival rate was 25%. Docetaxel was relatively well tolerated in this previously treated population. Grade IV neutropenia was common in patients (77%) but typically of brief duration. Febrile neutropenia was observed in 11 patients (14%), with no fatal infections. Severe fluid retention was rare (4% of patients). Conclusions: This multicenter phase II trial confirms antitumor activity and encouraging survival with docetaxel therapy in platinum-treated and platinum-refractory NSCLC. To validate these results, a phase III trial randomizing platinum-treated patients to docetaxel or best supportive care is underway.

AB - Purpose: Although several new chemotherapeutic agents are promising as primary therapy in non-small-cell lung cancer (NSCLC), few have demonstrated activity in platinum-refractory disease. Based on encouraging results reported in two single-institution studies of docetaxel in this setting, we performed a multicenter phase II trial evaluating this novel taxane in previously treated NSCLC patients prospectively categorized by platinum response status. Patients and Methods: Eighty patients with NSCLC previously treated with platinum-based chemotherapy received docetaxel at a dose of 100 mg/m2 intravenously over 1 hour, repeated every 21 days, accompanied by dexamethasone 8 mg orally twice daily for 5 days. Forty-seven patients (59%) were defined as platinum-refractory based on response status to prior therapy. Results: The median number of cycles delivered per patient was four (range, one to 21 cycles). Partial response was observed in 13 (16%) of 80 of patients, with similar response rates in platinum-sensitive and platinum- refractory patients. The median survival time was 7 months, and the 1-year survival rate was 25%. Docetaxel was relatively well tolerated in this previously treated population. Grade IV neutropenia was common in patients (77%) but typically of brief duration. Febrile neutropenia was observed in 11 patients (14%), with no fatal infections. Severe fluid retention was rare (4% of patients). Conclusions: This multicenter phase II trial confirms antitumor activity and encouraging survival with docetaxel therapy in platinum-treated and platinum-refractory NSCLC. To validate these results, a phase III trial randomizing platinum-treated patients to docetaxel or best supportive care is underway.

UR - http://www.scopus.com/inward/record.url?scp=0033988085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033988085&partnerID=8YFLogxK

M3 - Article

C2 - 10623703

AN - SCOPUS:0033988085

VL - 18

SP - 131

EP - 135

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -